C4 Therapeutics Executive Compensation (FY25)
CCCC · Executive and director compensation, fiscal 2024 to 2025
The C4 Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): June 24, 2026
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
160 figures on this page: 155 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Andrew Hirsch: $5,239,784 → $2,940,975 (43.9% lower)
Say-on-pay support: 98.2% → 98.1% (0.1 points lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is C4 Therapeutics' chief executive and what were they paid?
Total compensation for Andrew Hirsch, President and Chief Executive Officer, came to $2,940,975 in fiscal 2025. Compared with the $5,239,784 reported for fiscal 2024, Hirsch's total was 43.9% lower.
What was C4 Therapeutics' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 98.1% of votes cast for or against in favor at the meeting held June 24, 2026.
Which companies are in C4 Therapeutics' peer group?
Companies named in the disclosed peer group include Adicet Bio, Inc., Arvinas, Inc., Black Diamond Therapeutics, Inc., Cullinan Therapeutics, Inc. and Editas Medicine, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Andrew Hirsch President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Leonard Reyno Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Kendra Adams Chief Financial Officer and Head of Corporate Affairs | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Andrew Hirsch President and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Leonard Reyno Chief Medical Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Kendra Adams Chief Financial Officer and Head of Corporate Affairs | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andrew Hirsch | Option | — | — | — | — | — | — | ◇ |
| Andrew Hirsch | RSU | — | — | — | — | — | — | ◇ |
| Kendra Adams | RSU | — | — | — | — | — | — | ◇ |
| Kendra Adams | Option | — | — | — | — | — | — | ◇ |
| Leonard Reyno | Option | — | — | — | — | — | — | ◇ |
| Leonard Reyno | RSU | — | — | — | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Kendra Adams | Option | ◇ | — | ◇ | 02/13/32 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 09/17/33 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 02/12/33 | |
| Option | ◇ | — | ◇ | 02/13/34 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 02/13/35 | |
| Andrew Hirsch | Option | ◇ | — | ◇ | 02/13/34 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 02/13/35 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 02/14/33 | |
| Leonard Reyno | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 07/09/33 | |
| Option | ◇ | — | ◇ | 02/13/34 | |
| Option | ◇ | — | ◇ | 02/13/35 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Andrew Hirsch
President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
Kendra Adams
Chief Financial Officer and Head of Corporate Affairs · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
Leonard Reyno
Chief Medical Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Ronald Harold Wilfred Cooper Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Utpal Koppikar | ◇ | — | ◇ | — | — | — | ◇ |
Donna Grogan | ◇ | — | ◇ | — | — | — | ◇ |
Stephen Hoerter | ◇ | — | ◇ | — | — | — | ◇ |
Laura Bessen | ◇ | — | ◇ | — | — | — | ◇ |
Owen P. Hughes Jr | ◇ | — | ◇ | — | — | ◇ | ◇ |
Kenneth C. Anderson | ◇ | — | ◇ | — | — | — | ◇ |
Stephen Fawell | ◇ | — | ◇ | — | — | — | ◇ |
Bruce Downey | ◇ | — | — | — | — | — | ◇ |
Andrew J. Hirsch served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Adicet Bio, Inc. ACET
- Arvinas, Inc. ARVN
- Black Diamond Therapeutics, Inc. BDTX
- Cullinan Therapeutics, Inc. CGEM
- Editas Medicine, Inc. EDIT
- Foghorn Therapeutics Inc. FHTX
- Fulcrum Therapeutics, Inc. FULC
- IGM Biosciences, Inc. IGMS
- Kymera Therapeutics, Inc. KYMR
- Lyell Immunopharma, Inc. LYEL
- Monte Rosa Therapeutics, Inc. GLUE
- Nkarta, Inc. NKTX
- Nurix Therapeutics, Inc. NRIX
- ORIC Pharmaceuticals, Inc. ORIC
- Poseida Therapeutics, Inc. PSTX
- Prelude Therapeutics Incorporated PRLD
- Relay Therapeutics, Inc. RLAY
- Tango Therapeutics, Inc. TNGX
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 24, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 18, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 20, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 15, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 22, 2022 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact C4 Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where C4 Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
160 figures on this page: 155 cited to the filing that reported them, 5 calculated from figures it prints.
155 cited to the filing
5 calculated from the filing
Documents cited
- 0001628280-26-045194Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-26-028104Compensation Discussion and Analysis · DIRECTOR COMPENSATION · Director Compensation · Outstanding Equity Awards at Fiscal Year End · and 1 more section
- 0001628280-25-032155Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-25-020466Summary Compensation Table
- 0001628280-24-029301
- 0001628280-23-022597
- 0001564590-22-024179Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “C4 Therapeutics executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/CCCC (accessed 2026).
Short form: data: Velarion
The C4 Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about C4 Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers C4 Therapeutics discloses
The companies named in CCCC's own disclosed peer group.
Arvinas, Inc.Black Diamond Therapeutics, Inc.Cullinan Therapeutics, Inc.Editas Medicine, Inc.Foghorn Therapeutics Inc.Fulcrum Therapeutics, Inc.IGM Biosciences, Inc.Kymera Therapeutics, Inc.Lyell Immunopharma, Inc.Monte Rosa Therapeutics, Inc.Nkarta, Inc.Nurix Therapeutics, Inc.ORIC Pharmaceuticals, Inc.Poseida Therapeutics, Inc.Prelude Therapeutics IncorporatedRelay Therapeutics, Inc.Tango Therapeutics, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}